Format

Send to

Choose Destination
Curr Opin Cardiol. 2014 Sep;29(5):481-8. doi: 10.1097/HCO.0000000000000096.

Chelation therapy after the trial to assess chelation therapy: results of a unique trial.

Author information

1
Columbia University Division of Cardiology, Mount Sinai Medical Center, Miami Beach, Florida, USA.

Abstract

PURPOSE OF REVIEW:

EDTA chelation therapy has been in off-label use for the treatment of atherosclerosis. We review the results of the first large-scale randomized trial of this treatment.

RECENT FINDINGS:

The trial to assess chelation therapy was a $30 million National Institutes of Health-funded study of the safety and efficacy of EDTA-based chelation infusions in 1708 post-myocardial infarction (MI) patients. The trial to assess chelation therapy demonstrated a significant (P=0.035) 18% reduction in a combined primary endpoint of death, MI, stroke, coronary revascularization, or hospitalization for angina. In diabetic patients the benefit was more extreme, with a 41% relative reduction in risk (P=0.0002) and a 43% reduction in total mortality (P=0.011). Safety data were favorable. A reduction of oxidative stress by chelation of toxic metals has been proposed as a possible mechanism of action.

SUMMARY:

Recent research suggests that EDTA chelation may be a well-tolerated and effective treatment for post-MI patients. Future replication and mechanistic studies are important prior to implementation in all post-MI patients.

PMID:
25023079
PMCID:
PMC4162329
DOI:
10.1097/HCO.0000000000000096
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center